Clinical Trial Update: Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial assessing the efficacy and safety of LX102 Gene Therapy for neovascular age-related macular degeneration (nAMD) is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration
• Wet Age-related Macular Degeneration

Drugs mentioned

• LX102 Gene Therapy

Snippet

Sponsor: Innostellar Biotherapeutics Co.,Ltd | Conditions: Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD | Phase 3 | Status: RECRUITING